Shome Avik, Mugisho Odunayo O, Niederer Rachael L, Rupenthal Ilva D
Buchanan Ocular Therapeutics Unit, Department of Ophthalmology, New Zealand National Eye Centre, University of Auckland, Auckland, New Zealand.
Department of Ophthalmology, New Zealand National Eye Centre, University of Auckland, Auckland, New Zealand; Auckland District Health Board, Auckland, New Zealand.
Drug Discov Today. 2021 Dec;26(12):2839-2857. doi: 10.1016/j.drudis.2021.06.017. Epub 2021 Jul 3.
Uveitis is a complex ocular inflammatory disease often accompanied by bacterial or viral infections (infectious uveitis) or underlying autoimmune diseases (non-infectious uveitis). Treatment of the underlying infection along with corticosteroid-mediated suppression of acute inflammation usually resolves infectious uveitis. However, to develop more effective therapies for non-infectious uveitis and to better address acute inflammation in infectious disease, an improved understanding of the underlying inflammatory pathways is needed. In this review, we discuss the disease aetiology, preclinical in vitro and in vivo uveitis models, the role of inflammatory pathways, as well as current and future therapies. In particular, we highlight the involvement of the inflammasome in the development of non-infectious uveitis and how it could be a future target for effective treatment of the disease.
葡萄膜炎是一种复杂的眼部炎症性疾病，常伴有细菌或病毒感染（感染性葡萄膜炎）或潜在的自身免疫性疾病（非感染性葡萄膜炎）。治疗潜在感染并结合皮质类固醇介导的急性炎症抑制通常可治愈感染性葡萄膜炎。然而，为了开发更有效的非感染性葡萄膜炎治疗方法，并更好地应对感染性疾病中的急性炎症，需要更深入地了解潜在的炎症途径。在本综述中，我们讨论了该疾病的病因、临床前体外和体内葡萄膜炎模型、炎症途径的作用以及当前和未来的治疗方法。特别是，我们强调了炎性小体在非感染性葡萄膜炎发展中的作用，以及它如何可能成为该疾病有效治疗的未来靶点。
Zotero 插件